Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

Jun 16, 2020
|
staff reporter

NEW YORK ─ Molecular diagnostics firm Immunexpress said Tuesday that it has been awarded a grant of up to $599,549 by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop its host response sepsis test, SeptiCyte Rapid, as a triage tool to help identify SARS-CoV-2 patients with an elevated risk for viral or secondary bacterial sepsis.

SeptiCyte Rapid is a gene expression assay that uses reverse-transcription PCR to quantify the relative expression levels of host response genes isolated from whole blood.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Stricter Vaccine Standards

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Another Trial to Ramp Up

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Few Billion More

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Infectious Disease

  1. Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

  2. Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

  3. Centogene Reports 13 Percent Decline in Q2 Revenues

  4. Center for Genomic Regulation's COVID-19 Viral Beacon Digs Into Thousands of SARS-CoV-2 Genomes

    Premium

  5. FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.